热门资讯> 正文
Biomea Fusion sinks 25%, prices $40M stock offering
2025-06-18 14:39
- Clinical-stage diabetes and obesity company, Biomea Fusion (NASDAQ:BMEA) priced its previously announced underwritten public offering of 19.45M shares and accompanying warrants to buy the same number of shares.
- The underwriters have a 30-day option to purchase up to an additional 3M shares.
- The combined offering price of each share and accompanying common stock warrant is $2.00. The combined offering price of each pre-funded warrant and accompanying warrant is $1.9999.
- The gross proceeds are expected to be ~$40 million.
- The offering is expected to close on June 20, 2025.
- the stock price dropped about 25% on Tuesday during after market hours of trading.
More on Biomea Fusion
- Biomea Fusion launches public offering of stock and warrants; shares down 23%
- Biomea Fusion appoints Mick Hitchcock to succeed Thomas Butler as interim CEO
- Seeking Alpha’s Quant Rating on Biomea Fusion
- Historical earnings data for Biomea Fusion
- Financial information for Biomea Fusion
推荐文章
港股周报 | 中国大模型“春节档”打响！智谱周涨超138%；巨亏超230亿！美团周内重挫超10%
一周财经日历 | 港美股迎“春节+总统日”双假期！万亿零售巨头沃尔玛将发财报
一周IPO | 赚钱效应持续火热！年内24只上市新股“0”破发；“图模融合第一股”海致科技首日飙涨逾242%
从软件到房地产，美国多板块陷入AI恐慌抛售潮
Meta计划为智能眼镜添加人脸识别技术
危机四伏，市场却似乎毫不在意
美股机会日报 | 降息预期升温！美国1月CPI年率创去年5月来新低；净利、指引双超预期！应用材料盘前涨超10%
财报前瞻 | 英伟达Q4财报放榜在即！高盛、瑞银预计将大超预期，两大关键催化将带来意外惊喜？
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
